Patient Defense at Point of Care
What to bring
to the room.
What to measure
before and after.
A dead cell in a vial is not a failed treatment. It is a successful extraction of your money. The devices below tell you in under 30 seconds whether what is in that vial is alive. The biomarkers below tell you whether anything actually changed in your body. Both matter. Neither is optional if you are serious about this.
<30s
Viability result with best-in-class device
4
Checkpoints: baseline · injection · 30-day · 90-day
Without a baseline measurement before treatment, there is no outcome to evaluate. This is the most basic rule in medicine and the one most consistently violated by commercial stem cell clinics.
The honest disclaimer — read this first.
Viability is necessary but not sufficient. A cell counter tells you whether the cells are alive. It cannot tell you whether they are the cell type claimed, whether they are potent, sterile, or the right dose. A high viability score from a cell you cannot identify is still a cell you cannot evaluate. These devices are your last-mile defense — not a replacement for the COA, the manufacturer verification, and the 12-question Provider Challenge Sheet. Use them together or do not bother.
The Science First
What viability means. What it doesn't.
Before you rent a cell counter, understand what you are and are not learning from it.
Viability is the percentage of living cells in a sample. Dead cells cannot repair, modulate, or do anything useful in your body. They are debris. The FDA requires viability testing as a release criterion for all 31 approved cell therapy products. Of the 104 documented potency tests across those products, viability and cell count measures are the most common — accounting for 52% of non-redacted tests. It is the minimum floor of quality assurance, not the ceiling.
What viability does not tell you: cell identity, potency, sterility, dose adequacy, or mechanism fit. Those require the COA and lab documentation the provider should have before you arrive. What the cell counter adds is the post-shipping, post-thaw, at-your-bedside verification that what was once alive at the manufacturer is still alive when it reaches you. Viability degrades after thaw. A product that was 92% viable when it left the lab may be 60% viable four hours later if cold chain was broken. No COA captures that. Only a device at point of care does.
The minimum acceptable viability for most commercial MSC products at the time of administration is 70%. GMP manufacturers typically target 80–95% at release. Below 70% at bedside is a documented quality failure. Below 50% is a hard stop.
Clinical consensus · FDA-approved CTP release criteria · ISO 23033
The Devices
What to bring. What to rent. What to ask about.
Ranked by portability and practical applicability at a commercial clinic. All are real, commercially available instruments.
Portable
Buy or Rent · Best for Patients
Scepter 3.0 Cell Counter
MilliporeSigma (Merck)
The only truly handheld automated cell counter. Coulter impedance technology — measures cells by electrical resistance as they pass through a microfabricated sensor. Battery-operated. No dyes required. Fits in a coat pocket. Results in seconds.
MethodCoulter impedance — size and volume, not image
SpeedSeconds from a 20µL sample
OutputCell count + size distribution (pair with trypan blue for viability %)
PowerBattery operated — no mains required
SizeHandheld — pocket-sized
~$2,000–$3,500 purchase · ~$150–$300/week rental
Verdict: Most practical for bringing to a clinic. Pair with trypan blue manual confirmation for a full viability read. Rental: LabX, BioSurplus, university equipment programs.
Compact
Buy · Semi-Portable · Gold Standard
Countess 3 Automated Cell Counter
Thermo Fisher Scientific (Invitrogen)
Machine-learning image analysis using trypan blue exclusion. Returns cell count, viability %, and mean cell diameter in under 30 seconds from a 10µL sample on a disposable slide. Industry standard for cell therapy QC worldwide.
MethodBrightfield + trypan blue — live clear, dead dark
Speed<30 seconds per sample
OutputTotal cells/mL, % viability, mean diameter
ComplianceOptional 21 CFR Part 11 software — audit-trail records
SlidesDisposable — $40–$80 per 50-pack
~$3,500–$5,000 purchase · ~$200–$400/week rental
Verdict: Best all-round point-of-care choice. If your provider already has this on-site and uses it before every administration, that alone is a quality signal. Rental: Excedr, Thermo Fisher rental program, Labroots Equipment Leasing.
Compact
Buy · Best for MSCs Specifically
NucleoCounter NC-200
ChemoMetec
Closed cassette AO/DAPI dual fluorescence. More sensitive than trypan blue — distinguishes necrotic from apoptotic cells. Validated specifically for mesenchymal stem cells, which trypan blue consistently over-counts. GMP compliant, 21 CFR Part 11.
MethodAO/DAPI fluorescence — live vs dead cell distinction
Speed~60 seconds per sample
MSCValidated protocol for mesenchymal stem cells
GMP21 CFR Part 11 compliant — defensible audit records
SafetyClosed cassette — no dye exposure
~$8,000–$15,000 purchase · ~$500–$800/week rental
Verdict: The right tool if your provider is administering MSCs — which most commercial clinics are. Trypan blue overestimates viability for MSCs; this device does not. Rental: Excedr, BioSurplus, ChemoMetec direct.
Clinic-Sited
Ask the Provider to Have This
Vi-CELL XR Cell Viability Analyzer
Beckman Coulter
Fully automated trypan blue analysis with aspiration from a sample tube. 50-image capture with automated analysis. Standard instrument in cell therapy manufacturing QC departments globally. Not portable — but any serious clinical operation should own one.
MethodAuto trypan blue aspiration — 50-image brightfield
Speed~3–5 minutes including aspiration
OutputTotal, viable, nonviable counts; mean diameter; viability %
SizeFull benchtop — clinic-sited only
~$20,000–$35,000 purchase
Verdict: You won't bring this yourself. But ask whether the clinic has it. A commercial cell therapy clinic without a Vi-CELL, NucleoCounter, or equivalent on-site is operating without basic QC infrastructure. Absence is data.
Manual
Buy · Last Resort · ~$80 Total
Disposable Hemocytometer + Trypan Blue
Millicell (Merck) · Multiple suppliers
The original method. A gridded glass chamber + trypan blue dye + a microscope. Manual counting by a trained eye. Dead cells stain blue, live cells stay clear. Results in 5–10 minutes. Subject to operator variability and consistently overestimates viability.
MethodManual trypan blue exclusion under microscope
Speed5–10 minutes — technician-dependent
AccuracyHigh variability — trypan overestimates viability vs fluorescence
RequiresA microscope (any clinic should have one)
$50–$120 total supply cost
Verdict: Last resort only. If a provider cannot perform even this basic check, that is a serious signal. But do not rely on it as your only verification — trypan blue overestimates, and manual counting introduces human error.
Emerging · 2025
Research Stage · Watch This Space
On-Chip 3D Microfluidic Potency Assay
Nature Communications · May 2025 · Academic
A microfluidic chip that cultures cells in a 3D environment and measures secreted proteins to predict clinical outcomes — not just whether cells are alive, but whether they will work. Validated for BMAC in knee osteoarthritis. 24-hour assay. Not yet commercially available.
MeasuresImmunomodulatory + trophic protein secretion
PredictsPatient pain outcomes — not just viability
Time24 hours — pre-procedure planning required
StatusAcademic — not commercially available in 2026
Not commercially available. Academic licensing stage.
Verdict: The future of point-of-care potency testing. First device shown to predict actual patient pain outcomes from cell samples. When commercial versions emerge, this page updates. Watch for it.
Where to Get These Devices
Buy, rent, borrow, or demand.
You do not need to own a cell counter. The laboratory equipment rental market is real, accessible, and almost entirely unused by patients.
| Source | What's Available | Cost | Lead Time | Best For |
|---|---|---|---|---|
| Excedr (excedr.com) | Countess 3, NucleoCounter NC-200, broad cell analysis inventory — flexible lease terms | $150–$800/week | 1–5 business days | Patients with a scheduled date and a budget |
| LabX (labx.com) | Used and rental automated cell counters — Scepter, Countess, hemocytometer systems | $100–$500/week | 3–7 business days | Budget rentals — verify calibration certificate |
| BioSurplus (biosurplus.com) | Refurbished and rental instruments — Vi-CELL, Countess, NucleoCounter | $200–$600/week | 3–10 business days | Short-term rentals with calibration documentation |
| University core facilities | Full instrument access including NucleoCounter and flow cytometry | $30–$150/hour | 1–2 weeks advance booking | Patients near a research university — call the core facility directly |
| Your provider — ask them | Any credible cell therapy clinic should already have a Countess or equivalent | $0 additional cost | Request in writing 48 hrs before | The right first ask — before renting anything yourself |
| Thermo Fisher rental | Countess 3 direct from manufacturer — calibrated and supported | ~$300–$600/week | 5–10 business days | Patients who need manufacturer-backed calibration documentation |
In the Room · Before the Needle
The exact sequence. Step by step.
These are not theoretical. These are the specific steps to take when you are in the procedure room.
1
48 Hours Before
Notify the provider in writing that you will bring a device and request a sample before administration.
Email only — creates a written record. Exact language: "I will be bringing a cell viability counter. I am requesting a 20 microliter sample from the product lot for viability testing before administration. Please confirm." If they refuse — that is your answer. Do not proceed.
2
In the Room · First
Match the lot number on the vial to the lot number on the COA. Exactly.
Takes 30 seconds. If they do not match — or if no COA exists — stop. Request a written explanation before anything else happens. This is not being difficult. This is basic pharmaceutical accountability.
3
In the Room · Second
Ask when the lot was thawed. The clock starts at thaw — not at manufacture.
Most MSC products must be administered within 1–4 hours of thaw. If it was thawed yesterday or more than four hours ago, your actual viability will be substantially lower than the COA states. The COA viability is measured at release. Time and temperature erode it from that moment forward.
4
In the Room · Third
Request a 20 microliter sample. Run it through your device before anything is administered.
20µL is approximately 4 drops — trivial from any multi-dose product. For the Countess 3: mix 10µL sample with 10µL trypan blue, load on disposable slide, insert, read. Result in 30 seconds. Record the viability number, the time, and the lot number. Photograph the screen. This is your documentation.
5
Interpret the Number
What each viability result means.
Above 80%: Consistent with GMP release specs for most MSC products. Proceed if all other documentation checks out.
70–80%: Borderline. Ask the provider to explain the gap between COA release viability and current reading. If COA showed 92% and you see 72%, something happened in shipping or storage. Request the temperature log.
Below 70%: Stop. Do not proceed. Ask for the product to be replaced. Document everything. This is a quality failure by any credible standard for commercial cell therapy.
Below 50%: Hard stop. Leave. More than half the cells in that vial are dead. There is no acceptable clinical rationale for administering this.
70–80%: Borderline. Ask the provider to explain the gap between COA release viability and current reading. If COA showed 92% and you see 72%, something happened in shipping or storage. Request the temperature log.
Below 70%: Stop. Do not proceed. Ask for the product to be replaced. Document everything. This is a quality failure by any credible standard for commercial cell therapy.
Below 50%: Hard stop. Leave. More than half the cells in that vial are dead. There is no acceptable clinical rationale for administering this.
Social Protocol
What is courtesy. What is right. What is stupid.
Bringing a cell counter to a procedure room is unusual. Here is how to navigate it.
What Is Courtesy
Notify in advance. Be calm. Be professional.
- Email the provider 48 hours ahead — do not arrive with the device unannounced
- Frame it as standard quality assurance, not accusation. "I do this for all procedures involving biologics" is a reasonable framing
- Ask where in the room you can set up the device so you are not disrupting the procedure flow
- Thank the provider if they already have a device on-site and offer to use theirs instead
- Keep the sample request to 20µL maximum — do not ask for more than you need
What Is Right
You have an absolute right to verify what goes into your body.
- Requesting a viability test before administration is not confrontational — it is the minimum standard at any legitimate GMP-affiliated operation
- Asking to see the COA is not paranoia — it is standard pharmaceutical practice for any biologic
- Recording the viability result is your right as a patient — it is your body and your $15,000–$50,000
- Stopping the procedure based on a bad viability read is the correct decision — not a disruption
- Sharing your viability results with your home physician is the right thing to do regardless of outcome
What Is Stupid
Things that undermine you, your result, or your safety.
- Arriving with a device but accepting "we don't do that here" without getting it in writing — if they refuse testing, you need that refusal documented
- Trusting a viability result from an uncalibrated or borrowed device with no documentation — an uncalibrated result is worse than no result
- Using trypan blue manual counting as your only check — it consistently overestimates viability for MSCs
- Proceeding after a below-70% result because "the doctor said it's fine" — the number is the number
- Not measuring your pre-treatment baseline biomarkers — see the next section. Without a baseline, you can never know if anything changed
Pre and Post Measurement
Without a baseline, there is no outcome.
This is the most important section of this guide. A viability test tells you whether the product was alive going in. Pre/post biomarker measurement tells you whether anything actually happened after. Without both, you are flying blind — and the provider has no professional accountability for the result.
Why this matters: In every legitimate clinical trial, baseline measurements are mandatory — not optional. The reason is simple: without knowing where a patient started, you cannot evaluate where they ended. A patient who reports "feeling better" after a $30,000 stem cell procedure may have improved because of the treatment, because of the placebo effect, because of concurrent lifestyle changes, or because the condition naturally fluctuates. Without a baseline and a follow-up using validated measurement instruments, no one — including the provider — can tell the difference. This ambiguity protects the provider. It does not protect you.
The measurement timeline — four mandatory checkpoints
When
What You Are Measuring and Why
T−7
1 week before
Baseline — the most important measurement you will ever take.
This is your starting line. Every measurement after treatment is meaningless without it. Get your bloods drawn, complete your functional assessments, document your pain or functional scores. If the provider does not offer to do this, you must arrange it yourself through your primary care physician or a concierge lab. Do it in the week before treatment — not months before, when your condition may have changed.
This is your starting line. Every measurement after treatment is meaningless without it. Get your bloods drawn, complete your functional assessments, document your pain or functional scores. If the provider does not offer to do this, you must arrange it yourself through your primary care physician or a concierge lab. Do it in the week before treatment — not months before, when your condition may have changed.
T0
Day of injection
Point-of-care viability check + document the procedure.
This is where your cell counter is used. Record: viability %, lot number, time of thaw, time of administration, route, volume, and the name of the administering physician. Photograph everything. This is your procedural record — the document that exists if something goes wrong or nothing changes.
This is where your cell counter is used. Record: viability %, lot number, time of thaw, time of administration, route, volume, and the name of the administering physician. Photograph everything. This is your procedural record — the document that exists if something goes wrong or nothing changes.
T+30
30 days post
Early inflammation and safety markers. First functional check.
Repeat your blood panel. Check CRP, CBC, and any condition-specific markers. Most trials record their first checkpoint here. Inflammation reduction — if it is happening — shows up in bloods within 30 days. Functional improvements in orthopedic conditions typically emerge between 30–90 days. Any adverse effects that haven't resolved should be documented and discussed with your home physician now.
Repeat your blood panel. Check CRP, CBC, and any condition-specific markers. Most trials record their first checkpoint here. Inflammation reduction — if it is happening — shows up in bloods within 30 days. Functional improvements in orthopedic conditions typically emerge between 30–90 days. Any adverse effects that haven't resolved should be documented and discussed with your home physician now.
T+90
90 days post
Primary outcome window. Most peer-reviewed trials define success here.
The majority of published stem cell therapy trials define their primary endpoint at 90 days. Repeat every measurement from your baseline. Compare using the same validated instruments in the same conditions. This is when you can make a defensible, evidence-based determination about whether the treatment worked for you specifically. Not because you feel different — because the numbers changed.
The majority of published stem cell therapy trials define their primary endpoint at 90 days. Repeat every measurement from your baseline. Compare using the same validated instruments in the same conditions. This is when you can make a defensible, evidence-based determination about whether the treatment worked for you specifically. Not because you feel different — because the numbers changed.
T+6mo
6 months post
Durability check. Peak functional improvement window for most indications.
For autoimmune and orthopedic conditions, peer-reviewed literature places peak functional improvement in the 3–6 month window. If you were going to improve, you should see it by now. If improvement has not materialized, this is the point at which an honest conversation with your home physician becomes necessary — not a repeat treatment purchase.
For autoimmune and orthopedic conditions, peer-reviewed literature places peak functional improvement in the 3–6 month window. If you were going to improve, you should see it by now. If improvement has not materialized, this is the point at which an honest conversation with your home physician becomes necessary — not a repeat treatment purchase.
What to measure — biomarker by biomarker
These are the tests that matter. All are commercially available. Most are covered by standard health insurance panels when ordered by a physician. The prices below are direct-pay estimates from concierge labs.
Universal Blood Panel
C-Reactive Protein (CRP) — High Sensitivity
The most validated pre/post marker for stem cell therapy outcomes. Higher baseline CRP predicts worse outcomes after hematopoietic cell transplantation. Post-treatment reduction in CRP indicates the anti-inflammatory response is occurring. This is your single most important blood marker before and after any MSC treatment.
$15–$40 direct pay
Where: Any LabCorp, Quest Diagnostics, or concierge lab. Order through primary care physician or directly via Ulta Lab Tests, Walk-In Lab, or Similar platforms.
Universal Blood Panel
Complete Blood Count (CBC) with Differential
Establishes baseline immune cell populations. Post-treatment, monitors for unexpected immune activation, infection, or reaction. Essential for detecting any adverse hematological response within the first 30 days. If white cell counts change dramatically post-treatment, this is your early warning system.
$20–$50 direct pay
Where: LabCorp, Quest, any urgent care lab, or concierge services. Covered by most insurance when ordered by a physician with documented clinical indication.
Inflammation Markers
Interleukin-6 (IL-6)
Key pro-inflammatory cytokine. Baseline IL-6 assessment helps identify patients at higher risk for cytokine release syndrome. Post-treatment elevation of IL-6 is one of the earliest markers of adverse immune reaction. MSC therapy for diabetes has been shown to shift cytokine patterns from pro-inflammatory toward anti-inflammatory — IL-6 tracks this shift.
$40–$120 direct pay
Where: LabCorp Esoteric Testing, Quest Nichols Institute, or through a physician ordering a cytokine panel. Less commonly covered by insurance without documented inflammatory condition.
Orthopedic / Pain
Visual Analogue Scale (VAS) Pain Score
The most widely used validated pain measurement in stem cell orthopedic trials. A 0–10 scale that takes 30 seconds to complete. Simple — but only useful if you do it at baseline and repeat it identically at follow-up. "I feel better" is not a VAS score. "My VAS went from 7 to 3" is an outcome. Free. Takes 30 seconds. No physician required.
Free — self-administered
Where: VAS pain scales are freely available online. Download, print, complete, and date them. Keep copies. Photograph them. This is your functional record.
Orthopedic / Pain
WOMAC Index (Western Ontario and McMaster Universities Osteoarthritis Index)
The standard validated outcome measure for osteoarthritis trials — the indication for which most commercial MSC injections are sold. Measures pain, stiffness, and functional limitation across 24 questions. Used as the primary endpoint in the on-chip 3D microfluidic potency trial (Nature Communications, 2025). If your provider is not using WOMAC, they are not measuring what the science measures.
Free — self-administered
Where: Available freely from the WOMAC Osteoarthritis Index website and academic databases. Print, complete with a date, photograph, keep. Your baseline WOMAC score is the starting line.
Diabetes-Specific
HbA1c + C-Peptide + Fasting Insulin
The three measurements that define functional success in MSC therapy for type 1 and type 2 diabetes. MSC therapy has been shown in published trials to reduce HbA1c, increase C-peptide (a marker of insulin production), and reduce daily insulin requirements. Without baseline values for all three, you cannot evaluate whether the Vertex-style response occurred in you. These three numbers are your diabetes outcome record.
$60–$150 direct pay for all three
Where: LabCorp, Quest, or through your endocrinologist. Most diabetic patients already have recent HbA1c on file — use it as your baseline if dated within 4 weeks of treatment. Order C-peptide and fasting insulin additionally.
Neurological
Seizure Frequency Log (Epilepsy) / UPDRS (Parkinson's)
For neurological conditions, functional scales are the outcome. Seizure frequency is tracked as events per week — the Neurona Therapeutics trial reduced this from daily to weekly for some participants. UPDRS (Unified Parkinson's Disease Rating Scale) is the validated instrument for Parkinson's functional assessment. Neither requires a lab. Both require disciplined pre-treatment baseline documentation.
Free — clinician-administered or self-logged
Where: Seizure logs are self-maintained diaries. UPDRS is administered by a neurologist. Request a formal UPDRS assessment from your neurologist before treatment begins and repeat it at 90 days and 6 months.
Autoimmune / Inflammatory
Disease-Specific Activity Scores (EDSS for MS · SLEDAI for Lupus · CDAI for Crohn's)
Every major autoimmune indication has a validated disease activity score used in clinical trials. EDSS for multiple sclerosis. SLEDAI for lupus. CDAI for Crohn's disease. DAS28 for rheumatoid arthritis. These instruments exist because self-reported improvement is not a trial endpoint. If your provider is not using the validated scale for your condition, they are not practicing to clinical trial standards.
Free to $200 depending on whether clinician-administered
Where: Most are administered by your specialist. Request a formal scoring at your next pre-treatment appointment. Ask specifically: "Can you document my current EDSS score in writing?" That document is your baseline.
Imaging
MRI / X-ray / Ultrasound (Orthopedic) · MRI (Neurological)
For orthopedic indications, pre-treatment imaging establishes the structural baseline — cartilage thickness, joint space narrowing, disc height. Post-treatment imaging at 6 months documents whether structural changes occurred. For neurological indications, MRI can identify whether penumbral tissue — the tissue that responds to stem cell neuroprotection — was present at baseline. Without baseline imaging, structural changes after treatment are undocumented.
$200–$2,000 depending on modality and insurance
Where: Your specialist or hospital system. Request a copy of the imaging report AND the raw images (on CD or digital transfer). Keep both. The report without the images cannot be compared at follow-up if you change providers.
By condition — what to measure, where to get it, what it costs
| Condition | Pre-Treatment (Baseline) | Post-Treatment (90-day + 6-month) | Validated Scale | Cost (Direct Pay) |
|---|---|---|---|---|
| Knee / Joint Osteoarthritis | VAS pain score · WOMAC index · Joint X-ray or MRI · CRP · CBC | VAS · WOMAC · CRP · Optional repeat imaging at 6 months | WOMAC + VAS | $80–$300 (labs) + imaging if not covered |
| Spine / Disc | VAS pain score · Oswestry Disability Index · Lumbar MRI · CRP | VAS · Oswestry · CRP · Repeat MRI at 6 months | Oswestry Disability Index + VAS | $80–$200 labs + MRI cost |
| Type 1 Diabetes | HbA1c · C-peptide · Fasting insulin · Daily insulin dose log · CRP | HbA1c · C-peptide · Fasting insulin · Daily insulin dose at 3, 6, 12 months | HbA1c + C-peptide reduction + insulin independence | $60–$150 direct pay for full panel |
| Type 2 Diabetes / Metabolic | HbA1c · Fasting glucose · Fasting insulin · HOMA-IR · CRP · CBC | Full panel repeat at 90 days and 6 months | HbA1c + HOMA-IR | $80–$180 direct pay |
| Multiple Sclerosis | EDSS score (neurologist) · MRI brain + spine · CRP · CBC · Fatigue scale | EDSS at 90 days and 6 months · MRI at 6 months · CRP | EDSS (Expanded Disability Status Scale) | $80–$200 labs + neurologist visit + MRI |
| Lupus / RA / Autoimmune | SLEDAI or DAS28 (specialist) · ANA · Anti-dsDNA · CRP · ESR · CBC | Full panel repeat at 90 days and 6 months | SLEDAI (lupus) · DAS28 (RA) | $120–$300 for full autoimmune panel direct pay |
| Epilepsy | Seizure frequency log (4 weeks minimum) · EEG · Neurologist assessment · QoL scale | Seizure frequency log continuous · EEG at 6 months | Seizure frequency (events/week) + QoL | Seizure log: free. EEG: $200–$800. Neurologist: varies. |
| Parkinson's Disease | UPDRS (neurologist-administered) · MDS-UPDRS · Gait analysis · CRP | UPDRS at 90 days and 6 months · Gait analysis | MDS-UPDRS (Movement Disorder Society) | $0 if through existing neurologist. $300–$600 new neurologist visit. |
| Longevity / Anti-Aging | Biological age panel · CRP (hs) · IL-6 · CBC · Telomere length · VO2 max (optional) | Full panel repeat at 90 days and 12 months | No validated scale — document everything and define your own criteria in writing before treatment | $150–$600 depending on panel depth |
What it actually costs to measure properly
$0
Functional scales
VAS pain, WOMAC, seizure logs, EDSS — all free, self-administered or through your existing specialist
$80–150
Basic blood panel
CRP, CBC, IL-6 direct pay at LabCorp or Quest. Often covered by insurance with physician order.
$150–300
Cell counter rental
Countess 3 or Scepter 3.0 for one week via Excedr or LabX. The only cost you pay that is not covered by anything.
<1%
Of treatment cost
Total measurement cost is under 1% of what most commercial clinics charge. There is no excuse for skipping it.
Where to order your labs directly — no physician required
| Service | What They Offer | Price Range | Notes |
|---|---|---|---|
| Ulta Lab Tests (ultalabtests.com) | CRP, CBC, IL-6, HbA1c, C-peptide, full metabolic panels — direct consumer ordering | $15–$120 per test | Results sent to LabCorp or Quest — physician not required in most US states |
| Walk-In Lab (walkinlab.com) | Individual and panel ordering — CRP, inflammatory markers, thyroid, metabolic | $25–$200 | Results to your email — physician order not required. Draw at local partner lab. |
| LabCorp OnDemand (labcorp.com) | Direct-to-consumer lab ordering — broad panel availability | $30–$200 | Results through LabCorp patient portal within 1–3 business days |
| Quest Health (questhealth.com) | Consumer-direct lab ordering — wellness and disease panels | $30–$250 | Results within 1–5 business days. Physician order not required. |
| Function Health (functionhealth.com) | Comprehensive 100+ marker panel including biological age, inflammation, metabolic — annual membership | $499/year unlimited panels | Best for patients who want longitudinal tracking across all markers before and after treatment |
| Your primary care physician | Any test above — plus imaging referrals, UPDRS, EDSS, specialist coordination | Insurance co-pay or $0 | Ideal route. Puts measurement in your medical record. Creates documentation the provider cannot dispute. |
Country-by-Country Viability Standards
Where you are changes what is required of them.
The legal obligation to test viability before administration varies dramatically by country. In most commercial stem cell tourism destinations, there is no enforceable requirement at all.
United States
Strong
For FDA-Approved Products Only
FDA-approved CTPs require documented viability testing as a lot release criterion. However, the 700+ unapproved commercial clinics have no enforced viability testing requirement. Florida SB 1768 (2025) created a new gray zone for orthopedic and pain indications where state oversight applies but FDA enforcement is uncertain.
European Union
Strong
ATMP Regulation 1394/2007
EU regulation on Advanced Therapy Medicinal Products requires viability, identity, purity, and potency testing for substantially manipulated cell products. Hospital exemption allows some treatments outside this framework. EMA's Committee for Advanced Therapies enforces standards for approved products — but medical tourism clinics operating under hospital exemptions face lighter scrutiny.
Japan
Strong
Act on Safety of Regenerative Medicine (2014)
Japan's 2014 regenerative medicine law created a conditional approval pathway with mandatory quality testing including viability. PMDA oversight applies to approved products. Japan is one of the few countries with specific legislation designed for regenerative medicine that includes patient protection provisions beyond standard pharmaceutical regulation.
Mexico
Weak
COFEPRIS Oversight — Variable Enforcement
Mexico is the most common cross-border stem cell treatment destination for US patients. COFEPRIS is the regulatory authority but enforcement against unapproved commercial clinics is inconsistent. No mandatory point-of-care viability testing requirement exists for commercial stem cell offerings. Most treatments are cash-only, undocumented, and outside any quality framework.
Panama / Costa Rica
Weak
Minimal Regulatory Framework
Popular medical tourism destinations for US and European stem cell patients. Both countries lack specific regenerative medicine legislation. General pharmaceutical regulations apply but are not designed for cell therapy products. No enforced viability testing standard exists. Patient recourse in the event of adverse events is extremely limited.
Germany / Switzerland
Strong
EU ATMP Framework + National Strictness
Among the strongest regulatory environments for cell therapy in the world. Germany's Paul-Ehrlich-Institut and Swiss Medic both apply rigorous ATMP standards. Quality testing including viability is mandatory for approved products. Commercial unapproved clinics face meaningful legal exposure. If pursuing stem cell therapy in Europe, these are the highest-standards jurisdictions.
China
Moderate
NMPA Reform — Uneven Implementation
China has invested heavily in stem cell research and has approved specific cell therapies (CT-053 for myeloma). NMPA oversight has strengthened since 2016 reforms. However, a significant underground commercial market exists outside the approved framework. Quality standards vary enormously between approved hospital programs and commercial clinics targeting medical tourists.
India
Moderate
CDSCO Oversight — Growing Framework
India's Central Drugs Standard Control Organisation has issued guidelines for stem cell research and therapy. A 2019 National Guidelines document established standards for approved stem cell facilities. Enforcement against unapproved commercial clinics is limited. India is a growing medical tourism destination for stem cell treatments — quality varies enormously by facility.
Thailand / Philippines
Weak to None
Limited Specific Regulation
Both are active stem cell medical tourism destinations. Thailand's FDA and the Philippines' FDA have general pharmaceutical authority but lack specific stem cell quality frameworks with enforced viability testing requirements. Commercial clinics in both countries operate with minimal documentation requirements. Patient recourse after adverse events is practically nonexistent.
New Quiz Questions — Addendum to Assessment
Four questions that should be in every assessment.
These questions address device verification and pre/post measurement — the two dimensions not covered in the original 18-question engine. Add them to the Manus build as questions 19–22, or as a supplemental measurement readiness module.
New Q — Device Verification
Will the provider test viability of the product before administering it to you?
Yes — they have a cell counter on-site and test every lot before administration
They said yes when I asked — I have it confirmed in writing
They said it isn't necessary — the COA is sufficient
This has never been discussed and I haven't asked
Why it matters: The COA viability was measured at release — not at your bedside. Viability degrades after thaw. A product that was 92% viable when it left the manufacturer may be significantly lower when it reaches you if cold chain was broken or time exceeded. Point-of-care testing is the only measurement that protects the patient at the moment that matters.
New Q — Baseline Measurement
Have you established a documented baseline of your current condition before treatment begins?
Yes — blood work, functional scale, and imaging documented within the last 4 weeks
Partially — some baseline measurements taken but not comprehensive
No — I haven't done any pre-treatment measurements yet
The provider said baseline measurements aren't part of their protocol
Why it matters: Without a baseline, there is no outcome to evaluate. A provider who does not require pre-treatment measurement has no professional accountability for whether the treatment worked. If you don't measure where you started, the result is neither success nor failure — it is simply unknowable.
New Q — Follow-up Plan
Is there a structured post-treatment measurement plan — with defined checkpoints and validated instruments?
Yes — 30-day, 90-day, and 6-month checkpoints with named validated measurement instruments
Partially — some follow-up, but no defined instruments or checkpoints
They said to follow up "if I have concerns"
No follow-up plan has been discussed
Why it matters: "Follow up if you have concerns" is not a measurement protocol. It is an exit strategy. A provider who has no interest in measuring whether their treatment worked is a provider who has no professional stake in your outcome. Every published stem cell trial has defined checkpoints. Commercial providers should too.
New Q — Cold Chain Documentation
Has the provider disclosed the shipping and storage conditions for the product — including temperature log from manufacturer to clinic?
Yes — temperature-controlled shipping documented with monitoring log available on request
Partially described — some details provided but no temperature log offered
They said their supplier handles it — no details provided
Cold chain has never been mentioned
Why it matters: Cellular products are alive. A temperature excursion — even brief — can compromise viability and sterility without any visible sign. A provider who cannot produce a temperature log for the shipping of a live biological product is not operating at clinical trial standards. This is the gap that point-of-care viability testing was designed to catch.
The Legal Argument
Why viability testing at point of care should be mandatory. Everywhere.
The case for a new standard of care — stated plainly.
No country currently mandates point-of-care viability testing as a condition of commercial stem cell administration. The FDA requires it for approved products at the manufacturing release stage. The EMA requires it under ATMP regulation. But in the commercial, unapproved, direct-to-consumer stem cell market that operates across 700+ US clinics and thousands more internationally — there is no enforceable requirement to verify that what is in the vial is still alive at the moment it enters a patient's body.
This is a structural patient safety gap. The gap exists because the regulatory frameworks were designed for pharmaceutical manufacturing — not for a commercial market that sells thawed biologics four hours after delivery in clinics with no quality infrastructure. The COA at manufacture cannot verify what the cold chain delivered to your arm.
The argument for mandatory point-of-care viability testing is simple: if a pharmaceutical company were required to prove a drug is chemically active before dispensing it, the same standard should apply to a cell therapy clinic before injecting it. The cell is the drug. The drug must be alive to work. Verifying that it is alive requires a device. The device exists. The cost is under $400 for a one-week rental. There is no technical barrier to making this standard practice. There is only the absence of a legal requirement to do it.
Until that requirement exists, this is your responsibility — because no one else has been assigned it.
Take the full assessment before you decide anything.
The Stem Cell Readiness Index scores nine dimensions of your specific offer — including supply chain, evidence fit, measurement rigor, and provider competence.